Skip to content

Valsartan/Hydrochlorothiazide

    DEA Class; Rx

    Common Brand Names; Diovan HCT

    • ARB/HCTZ Combos

    Angiotensin II blocker and thiazide diuretic once-daily product
    Used for hypertension
    Additive efficacy; less potassium loss than with hydrochlorothiazide alone.

    Indicated for the treatment of hypertension.

     

    Hypersensitivity to valsartan, hydrochlorothiazide, or sulfonamides

    Anuria

    Coadministration with aliskiren in patients with diabetes

    Valsartan

    • Hyperkalemia (4-10%)
    • Dizziness (2-8%)
    • Hypotension (1-7%)
    • Fatigue (3%)

    Hydrochlorothiazide

    • Anaphylaxis
    • Anemia
    • Anorexia
    • Confusion
    • Dizziness
    • Epigastric distress
    • Erythema multiforme
    • Exfoliative dermatitis, including toxic epidermal necrolysis
    • Headache
    • Hyperuricemia
    • Hypokalemia or hypomagnesemia
    • Orthostatic hypotension
    • Photosensitivity
    • Stevens-Johnson syndrome

    Hypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of allergy or bronchial asthma, but are more likely in patients with such a history

    Thiazide diuretics have been reported to cause exacerbation or activation of systemic lupus erythematosus

    Orthostatic hypotension risk: Initiate combination therapy with 2 antihypertensive drugs cautiously in patients with diabetes or autonomic dysfunction and in geriatric patients

    Use with caution in severe hepatic impairment

    With CrCl <30 mL/min use loop diuretic instead of hydrochlorothiazide

    Dual blockade of the renin-angiotensin system with ARBs, angiotensin-converting enzyme (ACE) inhibitors, or aliskiren is associated with increased risk of hypotension, hyperkalemia, and altered renal function (including acute renal failure) in comparison with monotherapy

    Phototoxicity may occur; instruct patients to protect skin from sun and undergo regular skin cancer screening

    Angiotensin system during second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death

    There is limited information regarding presence of drug in human milk, effects on breastfed infant, or on milk production; valsartan is present in rat milk; hydrochlorothiazide is present in human breast milk

    Adults

    320 mg/day PO valsartan and 25 mg/day PO hydrochlorothiazide.

    Geriatric

    320 mg/day PO valsartan and 25 mg/day PO hydrochlorothiazide.

    Adolescents

    Safety and efficacy have not been established.

    Children

    Safety and efficacy have not been established

    Valsartan/hydrochlorothiazide

    tablet

    • 80mg/12.5mg
    • 160mg/12.5mg
    • 320mg/12.5mg
    • 160mg/25mg
    • 320mg/25mg